Momentum Pharma

Momentum Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and immune-mediated diseases. The company's lead candidate, MP-001, is a novel, long-acting prodrug of a corticosteroid designed to provide sustained therapeutic levels while minimizing systemic side effects. Currently, MP-001 is being evaluated in Phase 2 clinical trials for the prevention of acute graft-versus-host disease (aGvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation. Momentum is led by an experienced management team with a track record of successful drug development in the anti-infective and inflammation spaces.